PedAM
Pediatric Disease Annotations & Medicines
| Disease | thromboembolism |
| Phenotype | C0018801|heart failure |
| Sentences | 16 |
| PubMedID- 21135601 | Several studies that have attempted to address this controversy have, as a whole, demonstrated that the rates of thromboembolic events in patients with systolic heart failure taking warfarin are similar to those in patients taking placebo, basically showing no additional protective benefit of warfarin. |
| PubMedID- 24683002 | Objectives: to determine whether long-term oral anticoagulation reduces total deaths, cardiovascular deaths and major thromboembolic events in patients with heart failure. |
| PubMedID- 21315215 | Background: despite the elevated risk for developing venous thromboembolic events in patients with heart failure, there are no randomized, double-blind, controlled trial data on the comparison of low-molecular-weight heparin with unfractionated heparin (ufh) in this patient population. |
| PubMedID- 22250920 | Venous thromboembolism in patients with heart failure: in-hospital and chronic use of anti-coagulants for prevention. |
| PubMedID- 22696335 | Objectives: to determine whether long-term oral anticoagulation reduces total deaths and/or major thromboembolic events in patients with heart failure. |
| PubMedID- 26136386 | Conclusion: the cha2ds2-vasc risk stratification scheme was able to provide prognostic information on future thromboembolic events in patients with heart failure in sinus rhythm. |
| PubMedID- 21676376 | This disease is associated with heart failure, high incidence of systemic thromboembolism complications or ventricular arrhythmia. |
| PubMedID- 23626438 | A 2002 cochrane systematic review found no evidence from long term randomized controlled trials (rcts) to recommend use of aspirin to prevent thromboembolism in patients with heart failure in sinus rhythm. |
| PubMedID- 26501990 | Platelet activation and vascular endothelial dysfunction may contribute to the observed increased risk of thromboembolic events in patients with chronic heart failure. |
| PubMedID- 23970363 | Therefore, carvedilol may reduce the risk of thromboembolic events in patients with heart failure, irrespective of beta2-receptor haplotype status. |
| PubMedID- 21396509 | Venous thromboembolism in heart failure: preventable deaths during and after hospitalization. |
| PubMedID- 20981179 | The efficacy and safety of the lmwh enoxaparin was also compared to ufh in the prevention of venous thromboembolic disease in patients with heart failure or severe respiratory disease. |
| PubMedID- 20186041 | Background: there is no consensus as to whether anticoagulation has a favorable risk:benefit in reducing thromboembolic events in patients with heart failure (hf) secondary to dilated cardiomyopathy who do not suffer from atrial fibrillation or primary valvular disease. |
| PubMedID- 26318604 | Assessment of the cha2ds2-vasc score in predicting ischemic stroke, thromboembolism, and death in patients with heart failure with and without atrial fibrillation. |
| PubMedID- 21295173 | The risk of thromboembolism in heart failure: does it merit anticoagulation therapy. |
| PubMedID- 20024492 | What is the appropriate approach to prevention of thromboembolism in heart failure. |
Page: 1